Multiplex polymerase chain reaction

Several Scientific Journals Publish Research by Herbalife Scientists Highlighting Global Product Testing Standards

Retrieved on: 
Monday, April 24, 2023
Research, Vitamins, Supplements, Other Retail, Fitness & Nutrition, Specialty, General Health, Health, Retail, Science, Other Science, Taste, Multiplex polymerase chain reaction, Validation, Herbal medicine, Direct electron ionization liquid chromatography–mass spectrometry interface, Composition, Integrated DNA Technologies, Patent Cooperation Treaty, Spectrometry, Chinese University of Hong Kong, PCT, Quality, Open access, Food industry, Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., Patent, Manuscript, MDPI, Master of Science, Medicine, Open Access Scholarly Publishing Association, Quality assurance, Control, Education minister, Accuracy and precision, Content, Safety, Dietary supplement, Book, Standardization, Herbalife, Food

Premier wellness company and community, Herbalife, announced today that five recent research studies by its team of Quality Assurance scientists have been published across several international peer-reviewed journals.

Key Points: 
  • Premier wellness company and community, Herbalife, announced today that five recent research studies by its team of Quality Assurance scientists have been published across several international peer-reviewed journals.
  • The articles share the company’s best practices in validating herbal ingredients, identifying compound sampling techniques and other processes involved in the rigorous testing that goes into Herbalife products around the world.
  • The acceptance and publication of these studies underscore the global nutrition company’s commitment to scientific research, transparency, and accountability, driving consumer confidence and helping people live their best lives.
  • Herbalife products, quality assurance and manufacturing processes have received numerous international awards attesting to its high-quality standards.

Promega and Henlius Developing Microsatellite Instability Companion Diagnostic IVD Kit for Serplulimab in China

Retrieved on: 
Thursday, August 5, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Genetics, Neutralizing antibody, IVD, Research, Promega, Industry, Oncology, IgG4-related ophthalmic disease, Degenerative disease, Technology, Polymerase chain reaction, Union, MMR, Cell biology, Government, Mab, NDAS, Review, GMP, ICI, National Medical Products Administration, Laboratory, Patient, US Foods, Neoplasm, Cancer, Genome, Mainland China, New Drug Application, DNA replication, Food and Drug Administration, Multiplex polymerase chain reaction, RNA, Immunotherapy, Microsatellite instability, DNA, Renal cell carcinoma, NDA, Drug development, National Music Publishers' Association, United Kingdom, R, Marie Cassidy, MSI, Vaccine, Pharmaceutical industry, Fine chemical, Promega, Henlius, PROMEGA, HENLIUS

Shanghai Promega Biological Products Co., Ltd. and Shanghai Henlius Biotech, Inc. will develop and commercialize a microsatellite instability (MSI) companion diagnostic IVD kit to identify cancer patients likely to benefit from serplulimab, a novel anti-PD-1 monoclonal antibody (mAb) developed by Henlius for the potential treatment of microsatellite instability-high (MSI-H) solid tumors.

Key Points: 
  • Shanghai Promega Biological Products Co., Ltd. and Shanghai Henlius Biotech, Inc. will develop and commercialize a microsatellite instability (MSI) companion diagnostic IVD kit to identify cancer patients likely to benefit from serplulimab, a novel anti-PD-1 monoclonal antibody (mAb) developed by Henlius for the potential treatment of microsatellite instability-high (MSI-H) solid tumors.
  • The kit will be available to doctors in the Chinese Mainland to screen for MSI and inform immunotherapy options.
  • The New Drug Application (NDA) of serplulimab was recently granted priority review by the National Medical Products Administration (NMPA) in China.
  • Promega has received innovation status and priority review by the NMPA in China and also intends to seek regulatory clearance for a Promega MSI IVD in China.

Biotech and Pharma Labs Performing Endpoint PCR Can Reduce Amplification Time to 15 Minutes With New Promega Reagent and Eppendorf Instrument Combination

Retrieved on: 
Tuesday, June 8, 2021
Health, Medical devices, Other Health, Other Science, Science, Pharmaceutical, Biotechnology, Natural sciences, Molecular biology, Biology, Branches of biology, Laboratory techniques, Biotechnology, Polymerase chain reaction, Amplifiers, Thermal cycler, Amplicon, Multiplex polymerase chain reaction, Draft:OpenPCR, Eppendorf, Promega Corporation, EPPENDORF, PROMEGA CORPORATION

Biotech and pharma labs performing endpoint polymerase chain reaction (PCR) can amplify samples in as little as 15 minutes with new Promega GoTaq Rapid Master Mix paired with the Eppendorf Mastercycler X50s thermal cycler .

Key Points: 
  • Biotech and pharma labs performing endpoint polymerase chain reaction (PCR) can amplify samples in as little as 15 minutes with new Promega GoTaq Rapid Master Mix paired with the Eppendorf Mastercycler X50s thermal cycler .
  • View the full release here: https://www.businesswire.com/news/home/20210608005085/en/
    Promega GoTaq Rapid Master Mix paired with the Eppendorf Mastercycler X50s thermal cycler enables labs performing endpoint polymerase chain reaction (PCR) to amplify samples in as little as 15 minutes.
  • The Promega and Eppendorf combination speeds time-to-results without sacrificing result quality or accuracy, enabling labs to address high sample volumes and backlogs.
  • The GoTaq Rapid Master Mix can decrease that time to 15 minutes or less, depending on instrument and target amplicon size.

Eurofins Launches a Rapid SARS-CoV-2 Antigen Test and a RT-PCR Test in a Self-Sampled, Gargling Format

Retrieved on: 
Monday, December 14, 2020
Biotechnology, General Health, Infectious diseases, Health, Medical Supplies, Branches of biology, Natural sciences, Molecular biology, Laboratory techniques, Articles, Amplifiers, Sarbecovirus, Coronavirus disease, Multiplex polymerase chain reaction, Polymerase chain reaction, Real-time polymerase chain reaction, Severe acute respiratory syndrome

The GSD NovaGen SARS-CoV-2 (COVID-19) antigen rapid test provides results from nasopharyngeal samples within 15 minutes.

Key Points: 
  • The GSD NovaGen SARS-CoV-2 (COVID-19) antigen rapid test provides results from nasopharyngeal samples within 15 minutes.
  • With diagnostic sensitivity of 92.6% and diagnostic specificity of 98.6%, the test meets WHO performance criteria (sensitivity 80%; specificity 97%) for use in the global fight against COVID-19.
  • The GSD NovaPrime SARS-CoV-2 (COVID-19) is a highly sensitive Multiplex Real-Time PCR test for the direct qualitative pathogen detection of SARS-CoV-2.
  • The multiplex PCR test allows for a streamlined workflow in one reaction and provides results in approximately one hour.

QIAGEN Launches NeuMoDx Multiplex Test to Complete Range of SARS-CoV-2 Testing Solutions in Europe and Other Markets

Retrieved on: 
Monday, November 16, 2020
Health, Medical devices, Infectious diseases, Technology, Other Technology, Research, Science, Respiratory diseases, Atypical pneumonias, Sarbecovirus, Infectious diseases, Branches of biology, Medical software, Qiagen, Respiratory syncytial virus, Emergency Use Authorization, Multiplex polymerase chain reaction, Severe acute respiratory syndrome, DiaSorin

With the Northern Hemisphere in the grip of flu season, this multiplex polymerase chain reaction (PCR) test detects and differentiates influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minutes.

Key Points: 
  • With the Northern Hemisphere in the grip of flu season, this multiplex polymerase chain reaction (PCR) test detects and differentiates influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minutes.
  • QIAGEN has launched NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage in the European Union and other markets after CE-IVD registration, and has submitted an Emergency Use Authorization (EUA) request to the FDA.
  • QIAGENs new respiratory test takes advantage of the NeuMoDx 96 and NeuMoDx 288 molecular systems automated three-step workflow.
  • In addition, QIAGEN has expanded specimen types that can be used on the existing NeuMoDx SARS-CoV-2 test.

Co-Diagnostics, Inc. Provides Update on "ABC" Test for Influenza A, Influenza B, and COVID-19

Retrieved on: 
Thursday, September 24, 2020
Natural sciences, Branches of biology, Laboratory techniques, Biology, Biotechnology, Molecular biology, Amplifiers, Molecular diagnostics, Polymerase chain reaction, Primer dimer, Real-time polymerase chain reaction, Multiplex polymerase chain reaction

"Our patented CoPrimer technology platform is ideally suited for multiplex reactions by substantially reducing 'primer-dimers,' a phenomenon in PCR molecular tests that results in false positive results.

Key Points: 
  • "Our patented CoPrimer technology platform is ideally suited for multiplex reactions by substantially reducing 'primer-dimers,' a phenomenon in PCR molecular tests that results in false positive results.
  • Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology.
  • The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA).
  • Readers of this press release are cautioned not to place undue reliance on any forward-looking statements.

Eurofins Diatherix Launches Flu Plus to Identify SARS-CoV-2 and Five Additional Viruses

Retrieved on: 
Monday, September 14, 2020
Medical Supplies, Health, FDA, Infectious diseases, Other Health, Pharmaceutical, Biotechnology, Natural sciences, Branches of biology, Amplifiers, Laboratory techniques, Molecular biology, Sarbecovirus, Physical sciences, Multiplex polymerase chain reaction, Eurofins Scientific, Polymerase chain reaction, Emergency Use Authorization, Severe acute respiratory syndrome

As a leader in respiratory viral and bacterial testing, Eurofins Diatherix is pleased to announce the development of Flu Plus, a new test added to its proprietary respiratory testing portfolio.

Key Points: 
  • As a leader in respiratory viral and bacterial testing, Eurofins Diatherix is pleased to announce the development of Flu Plus, a new test added to its proprietary respiratory testing portfolio.
  • Diatherix received Emergency Use Authorization from the FDA for their SARS-CoV-2 virus test on 22 April 2020.
  • Note: at this time, Eurofins Diatherix cannot accept specimens from the state of New York.
  • Eurofins Diatherix utilizes TEM-PCR (Target Enriched Multiplex Polymerase Chain Reaction), an innovative proprietary molecular technology, to deliver high throughput, one-day results.

Significant Multiplexing Benefits of Co-Diagnostics’ CoPrimer™ Tech Presented at PAG XXVIII

Retrieved on: 
Tuesday, January 14, 2020
Software, Research, General Health, Networks, Hardware, Technology, Agriculture, Natural Resources, Genetics, Science, Biotechnology, Health, Telecommunications, Natural sciences, Laboratory techniques, Branches of biology, Physical sciences, Polymerase chain reaction, Molecular biology, Amplifiers, Biotechnology, Biosearch Technologies, Multiplex polymerase chain reaction, Assay, Genotyping

The presentation, titled CoPrimer Assays for Multiplex PCR, described a study that involved developing several genotyping assays using BHQplex CoPrimer technology, the LGC, Biosearch -branded CoPrimers.

Key Points: 
  • The presentation, titled CoPrimer Assays for Multiplex PCR, described a study that involved developing several genotyping assays using BHQplex CoPrimer technology, the LGC, Biosearch -branded CoPrimers.
  • All different combinations of assays and plex-levels tested were shown to be successful in detecting the target sequences, without being inhibited by the multiplexing.
  • This included successfully enabling the multiplexed detection of a panel of 15 proprietary agricultural DNA targets.
  • Multiplex PCR has several cost, throughput, and economical advantages over single-plex PCR reactions, which advantages increase with the plex level.

Global Polymerase Chain Reaction (PCR) Market 2019-2025: Increasing Demand for PCR in Genetic and Molecular Testing

Retrieved on: 
Wednesday, December 4, 2019
Polymerase chain reaction, Natural sciences, Molecular biology, Laboratory techniques, Physical sciences, Branches of biology, Real-time polymerase chain reaction, Reverse transcription polymerase chain reaction, Digital polymerase chain reaction, Inverse polymerase chain reaction, Multiplex polymerase chain reaction, Nested polymerase chain reaction

DUBLIN, Dec. 4, 2019 /PRNewswire/ -- The "Polymerase Chain Reaction (PCR) Global Market - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 4, 2019 /PRNewswire/ -- The "Polymerase Chain Reaction (PCR) Global Market - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The factors driving the growth of PCR market are increasing demand for early detection of chronic diseases, increasing demand for genetic and molecular testing, high prevalence of infectious diseases, expiry of PCR patents of major players, increased investments in the field of companion diagnostics using PCR, increasing qPCR based food safety testing, technological advancements and growing demand for rapid diagnostic tests.
  • By Technique, the PCR market is segmented into standard PCR, real-time PCR, reverse transcriptase PCR, digital PCR, assembly PCR, multiplex PCR, Hot start PCR, and others.
  • Others include nested PCR, Inverse PCR, Immune PCR, anchored PCR, RACE PCR, asymmetric PCR, universal PCR, ISSR PCR, allele-specific PCR, ligation-mediated PCR, touchdown PCR, solid-phase PCR, methylation PCR, mini primer PCR, nanoparticle assisted PCR, overlap extension PCR, and In-situ PCR and long PCR.

Polymerase Chain Reaction (PCR) Market - Global Forecast to 2025: Market is Expected to Reach $12.9 Billion - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 4, 2019
Pharmaceutical, Health, Clinical trials, Medical devices, Natural sciences, Laboratory techniques, Molecular biology, Branches of biology, Physical sciences, Amplifiers, Polymerase chain reaction, Reverse transcription polymerase chain reaction, Multiplex polymerase chain reaction, Inverse polymerase chain reaction, Real-time polymerase chain reaction, Nested polymerase chain reaction

The "Polymerase Chain Reaction (PCR) Global Market - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polymerase Chain Reaction (PCR) Global Market - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The PCR market is expected to reach $12,910.1 million by 2025 growing at a high single-digit CAGR from 2019 to 2025.
  • By Technique, the PCR market is segmented into standard PCR, real-time PCR, reverse transcriptase PCR, digital PCR, assembly PCR, multiplex PCR, Hot start PCR, and others.
  • Others include nested PCR, Inverse PCR, Immune PCR, anchored PCR, RACE PCR, asymmetric PCR, universal PCR, ISSR PCR, allele-specific PCR, ligation-mediated PCR, touchdown PCR, solid-phase PCR, methylation PCR, mini primer PCR, nanoparticle assisted PCR, overlap extension PCR, and In-situ PCR and long PCR.